Revolution Medicines, Inc. - Common Stock (RVMD)

Historical Holders from Q1 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
RVMD on Nasdaq
Shares outstanding
186,164,820
Price per share
$79.65
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
191,763,478
Total reported value
$8,954,921,999
% of total 13F portfolios
0.02%
Share change
+1,001,009
Value change
+$87,457,260
Number of holders
316
Price from insider filings
$79.65
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revolution Medicines, Inc. - Common Stock (RVMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 7.9% +16% $435,923,419 +$63,471,970 13,262,045 +17% Dapice Joshua J. 31 Dec 2024
JANUS HENDERSON GROUP PLC 6.1% +6.7% $530,327,722 +$35,740,771 11,356,054 +7.2% JANUS HENDERSON GROUP PLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 5.5% $377,455,761 10,259,738 Wellington Management Group LLP 30 Jun 2025
FMR LLC 5% $439,058,769 9,401,687 FMR LLC 30 Sep 2025
BAKER BROS. ADVISORS LP 5% $358,678,428 9,364,972 Baker Bros. Advisors LP 30 Jun 2025
BlackRock, Inc. 4.5% $334,288,717 8,399,214 BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2025, Revolution Medicines, Inc. - Common Stock (RVMD) has 316 institutional shareholders filing 13F forms. They hold 191,763,478 shares. .

Top 25 institutional shareholders own 80% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.4% 15,663,094 -0.63% 0.01% $731,466,490
FARALLON CAPITAL MANAGEMENT LLC 7.9% 14,625,692 +2.1% 3.9% $683,019,816
JANUS HENDERSON GROUP PLC 6.1% 11,356,054 +7.2% 0.24% $530,307,153
WELLINGTON MANAGEMENT GROUP LLP 5.3% 9,813,436 -4.4% 0.08% $458,287,462
BAKER BROS. ADVISORS LP 5.1% 9,455,357 +0.97% 3.2% $441,565,172
FMR LLC 5.1% 9,401,687 +13% 0.02% $439,058,770
BlackRock, Inc. 4.5% 8,327,758 -3.9% 0.01% $388,906,300
Nextech Invest, Ltd. 4.1% 7,601,087 0% 54% $354,970,763
Paradigm Biocapital Advisors LP 3.3% 6,223,291 +2.1% 8.6% $290,627,690
Bellevue Group AG 3% 5,573,838 +22% 5.4% $260,298,235
STATE STREET CORP 2.8% 5,254,639 +11% 0.01% $245,391,641
T. Rowe Price Investment Management, Inc. 2.6% 4,782,318 +2% 0.14% $223,335,000
Alphabet Inc. 2.2% 4,133,277 0% 8% $193,024,036
BVF INC/IL 2.1% 3,974,913 -20% 7.5% $185,628,437
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 3,873,706 -18% 0.02% $180,903,000
DEERFIELD MANAGEMENT COMPANY, L.P. 2% 3,650,342 +7.9% 2.6% $170,470,971
Holocene Advisors, LP 1.8% 3,437,283 -5.4% 0.37% $160,521,116
GEODE CAPITAL MANAGEMENT, LLC 1.7% 3,145,640 +5.1% 0.01% $146,932,051
Woodline Partners LP 1.6% 2,915,883 +0.01% 0.64% $136,171,736
a16z Capital Management, L.L.C. 1.5% 2,748,523 0% 9.2% $128,356,024
Casdin Capital, LLC 1.4% 2,647,333 -8.3% 10% $123,630,451
WESTFIELD CAPITAL MANAGEMENT CO LP 1.4% 2,513,967 +52% 0.49% $117,402,259
JPMORGAN CHASE & CO 1.3% 2,498,327 -12% 0.01% $116,671,883
GENERAL ATLANTIC, L.P. 1.3% 2,474,428 3.5% $115,555,788
Lunate Capital Ltd 1.2% 2,196,200 0% 46% $102,562,540

Institutional Holders of Revolution Medicines, Inc. - Common Stock (RVMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 71,490 $6,618,404 +$537,245 $79.65 12
2025 Q3 191,763,478 $8,954,921,999 +$87,457,260 $46.70 316
2025 Q2 190,726,235 $7,017,009,498 -$4,134,286 $36.79 305
2025 Q1 191,051,104 $6,776,435,868 -$111,944,443 $35.36 280
2024 Q4 193,055,963 $8,445,467,181 +$749,026,007 $43.74 278
2024 Q3 168,830,185 $7,656,108,748 +$1,876,917 $45.35 252
2024 Q2 168,412,310 $6,536,360,101 +$376,492,769 $38.81 222
2024 Q1 158,827,884 $5,118,999,293 +$13,473,215 $32.23 205
2023 Q4 296,688 $8,528,142 +$6,436,357 $29.02 4
2023 Q3 111,953,251 $3,098,818,648 +$8,763,005 $27.68 163
2023 Q2 111,575,552 $2,984,131,046 +$99,855,971 $26.75 136
2023 Q1 108,080,099 $2,339,923,951 +$420,541,164 $21.66 147
2022 Q4 88,205,394 $2,101,077,413 +$33,054,778 $23.82 131
2022 Q3 81,009,621 $1,597,454,259 +$212,990,118 $19.72 128
2022 Q2 71,040,590 $1,384,537,160 +$38,056,673 $19.49 122
2022 Q1 73,938,192 $1,885,138,975 +$15,749,801 $25.51 121
2021 Q4 73,268,441 $1,844,183,801 -$50,186,441 $25.17 111
2021 Q3 72,282,662 $1,988,520,078 +$49,812,476 $27.51 111
2021 Q2 70,346,720 $2,232,691,951 +$90,768,509 $31.74 125
2021 Q1 66,423,819 $3,047,429,763 +$426,553,376 $45.88 125
2020 Q4 57,342,308 $2,270,190,182 +$131,226,916 $39.59 114
2020 Q3 56,953,491 $1,981,063,717 +$340,135,585 $34.80 87
2020 Q2 46,885,624 $1,478,096,925 +$22,726,406 $31.57 72
2020 Q1 46,880,534 $1,025,105,285 +$1,024,831,007 $21.91 71